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Background: Elevation of cardiac troponin has been documented in multiple settings without acute coronary
syndrome. However, its impact on long-term cardiac outcomes in the context of acute decompensated diabetes
remains to be explored.
Methods: We performed a retrospective analysis of 872 patients admitted to Temple University Hospital from
2004–2009 with DKA or HHS. Patients were included if they had cardiac troponin I (cTnI) measured within 24 hours
of hospital admission, had no evidence of acute coronary syndrome and had a follow up period of at least 18
months. Of the 264 patients who met the criteria, we reviewed the baseline patient characteristics, admission labs,
EKGs and major adverse cardiovascular events during the follow up period. Patients were categorized into two
groups with normal and elevated levels of cardiac enzymes. The composite end point of the study was the
occurrence of a major cardiovascular event (MACE) during the follow up period and was compared between the
two groups.
Results: Of 264 patients, 24 patients were found to have elevated cTnI. Compared to patients with normal cardiac
enzymes, there was a significant increase in incidence of MACE in patients with elevated cTnI. In a regression
analysis, which included prior history of CAD, HTN and ESRD, the only variable that independently predicted MACE
was an elevation in cTnI (p = 0.044). Patients with elevated CK-MB had increased lengths of hospitalization
compared to the other group (p < 0.001).
Conclusions: Elevated cardiac troponin I in patients admitted with decompensated diabetes and without evidence
of acute coronary syndrome, strongly correlate with a later major cardiovascular event. Thus, elevated troponin I
during metabolic abnormalities identify a group of patients at an increased risk for poor long-term outcomes.
Whether these patients may benefit from early detection, risk stratification and preventive interventions remains to
be investigated.
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Elevated cardiac biomarkers in decompensated diabetes
in the absence of an acute coronary syndrome (ACS)
have been described in several case reports [1-5]. While
non-ACS related cardiac biomarkers have been studied in
various acute and chronic medical conditions, acute de-
compensated diabetes has received less attention [1,5-12].
Acute decompensated diabetes and ACS, share a complex
dynamic that results in significant ambiguity when inter-
preting biomarker elevation in this setting [13-15]. Such
ambiguity is concerning because myocardial infarction has
been shown to be the most common cause of death within
the first 24 hours of admission for acutely decompensated
diabetes [16].
Recent studies have highlighted a novel relationship
between the severity of acidemia in acute decom-
pensated diabetes and abnormal elevations in cardiac
troponin-I (cTnI). Moller et al. describe patients in dia-
betic ketoacidosis with severe acidemia and abnormally
elevated cTnI who had no angiographic evidence of cor-
onary artery disease (CAD), leading them to suggest that
ketoacidemia may contribute to elevations in cardiac
enzymes [4].
Since the number of hospital discharges for acute de-
compensated diabetes has doubled since 1980 [17] and
the worldwide incidence of diabetes mellitus (DM) is
expected to double over the next 15 years [18-22], defin-
ing the importance of elevated cardiac biomarkers in
diabetic disorders is critical. In this study, we assessed
the clinical significance of abnormal elevations in cTnI
in decompensated diabetics.Figure 1 Flow Chart Identifying Patient Selection. Abbreviations: ACS =
HHNK = Hyperglycemic Hyperosmolar Non-Ketotic Syndrome.Methods
We performed a retrospective review of 872 charts for
patients admitted to Temple University Hospital (TUH)
with a diagnosis of “Diabetic Ketoacidemia” between
2004–2009. Approval for this chart review was obtained
from the Institutional Review Board. Inclusion criteria
required patients to have levels of cTnI within 24 hours
of admission, a history of prior or newly diagnosed
diabetes mellitus, and evidence of diabetic ketoacidemia
(DKA) or the hyperosmolar hyperglycemic state (HHS).
DKA and HHS were defined in accord with common
clinical practice [14,15]. 298 patients met inclusion
criteria.
For patients that met inclusion criteria, if levels of CK-
MB were also measured, serum values for both biomarker
sub-types were recorded. Patients were considered to have
abnormal elevations in cardiac biomarkers if either CK-
MB (0.00-7.50 ng/ml) or cTnI (0.05-0.40 ng/ml) were
above the hospital’s normal reference level.
Patients were excluded from the study if they had evi-
dence of acute coronary syndrome in accord with the
AHA/ACC Guidelines [18], or if the patient died during
the hospitalization. ECGs were analyzed retrospectively
by two separate physicians blinded to clinical outcomes.
An ECG was determined to be consistent with ACS if
there was ≥1 mm ST depression or ≥2 mm ischemic T
wave inversion, new Q- waves, new left bundle branch
block, or ST elevations consistent with ischemia. Of the
298 patients who met inclusion criteria, 34 were excluded
because of suspected or confirmed ACS, or death during
admission (See Figure 1). For the remaining 264 patients,Acute Coronary Syndrome; DKA = Diabetic Ketoacidosis;
Table 1 Descriptive statistics – continuous data
Variable Normal cTnI Elevated cTnI P value
Age(Years) 45.1 ± .88 50.3 ± 3.41 .081
Blood
Glucose (mg/dL) 690.0 ± 17.30 1045 ± 82.30 <0.001
Hemoglobin (gm/dL) 14.30 ± 0.27 12.50 ± 0.60 0.040
pH 7.18 ± 0.01 7.07 ± 0.04 <0.001
Anion Gap (mmol/L) 26.00 ± 0.42 28.13 ± 1.67 0.138
Creatinine (mg/dL) 2.40 ± 0.12 4.22 ± 0.58 0.004
Mean length of Follow Up (Months) 41.6 ± 1.31 37.9 ± 4.10 0.691
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Using the electronic medical record, Alpha Imaging
SystemsW, CentricityW, PACSW image viewer and EPICW,
both inpatient and outpatient medical records were
reviewed to record baseline patient characteristics, length
of hospital stay, length of follow up, and to assess the time
interval in months to the occurrence of a major adverse
cardiac event (MACE). MACE was defined as myocardial
infarction, percutaneous coronary intervention (PCI), cor-
onary artery bypass grafting (CABG), or death. Only the
first admission was included for patients admitted more
than once. chronic renal insufficiency was defined as base-
line creatinine above 1.4 mg/dL, end stage renal disease
(ESRD) was defined as patients on hemodialysis or peri-
toneal dialysis.
Statistical analysis
Continuous variables were expressed as mean ± SE and
statistical significance was tested using the Student t-
test. Categorical variables were analyzed using either the
chi-square statistic or Fischer exact test, as appropriate.
Patients were grouped as normal versus elevated based
upon serum admission cTnI levels. Multivariate logistic
regression models were constructed to determine vari-
ables that predicted abnormal elevations in admission
serum cTnI. Similar models were constructed to identifyTable 2 Descriptive statistics – categorical data
Variable Normal cTnI Elevated cTnI P value
%Male 50.0 50.0 .479
White (%) 20.5 20.8 .942
Black (%) 69.0 62.5 .942
Latino (%) 7.9 8.3 .942
Other (%) 2.5 4.2 .942
History of CAD (%) 4.6 41.7 <0.001
CRI (%) 9.7 12.5 0.66
ESRD (%) 2.1 8.3 0.07
Tobacco (%) 53.2 45.0 0.48
HTN (%) 45.6 69.6 0.028
Abbreviations: CAD = Coronary Artery Disease; CRI = Chronic Renal
Insufficiency; ESRD = End Stage Renal Disease; HTN = Hypertension.variables that independently predicted long term out-
comes. Linear regression models were constructed to
identify variables that predicted length of hospital stay.
Length of hospital stay and MACE were chosen as ob-
jective measures for short and long term outcomes re-
spectively. Kaplan-Meir plots were used to assess effects
over time. Associations were considered significant if
alpha < 0.05. All analyses were performed with SPSS. v19.0Measurement of cardiac troponin I
The blood specimens analyzed in this study were collected
in observation with routine precautions for venipuncture.
Blood samples were allowed to clot completely prior to
centrifugation and stored at room temperature (15 to 30°C)
for no longer than two hours.
Cardiac troponin I was measured by the Access AccuTni™
chemiluminescent immunoassay (Beckman CoulterW). This
assay uses two monoclonal antibodies in conjunction with
alkaline phosphatase to bind antigenic sites in the solidFigure 2 Survival Function in Months Between Based Upon
Serum Admission Biomarkers. Kaplan-Meier plot reveals
statistically significant survival in both the negative troponin group
compared to the positive troponin group (with maximum difference
over first two years).
Table 3 Study outcomes amongst subjects enrolled based upon serum admission cTnI
Variable Normal cTnI Elevated cTnI P value
MACE (%) 1.70 33.00 <0.001
MI (%) 1.70 33.00 <0.001
CABG (%) 0.00 0.00 -
PCI (%) 0.42 0.00 <0.001
Death (%) 0.00 4.20 <0.001
Mean Length of Hospital Stay (Days) 5.73 ± 0.37 11.04 ± 1.97 <0.001
Abbreviations: CAD = Coronary Artery Disease; CRI = Chronic Renal Insufficiency; ESRD = End Stage Renal Disease; HTN = Hypertension.
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monoclonal anti-cTnI antibody. The Access AccuTni™
chemiluminescent immunoassay has a cTnI cutoff of
0.4ng/mL, this cutoff yields the most optimal sensitivity
and specificity.Measurement of CK-MB
Similar to cTnI, CK-MB was also measured with the
Access AccuTni™ chemiluminescent immunoassay, with
a similar two monoclonal antibody system.Results
Demographic characteristics of the patient population
based upon serum admission cTnI and their clinical
measures at admission are shown in Tables 1 and 2. Of
264 patients, 24 patients were found to have elevated
cTnI. There were no statistically significant differences
in age, sex or ethnic makeup identified amongst the
studies participants when comparison was made based
upon patients with normal versus elevated admission
cTnI. Subjects with elevated admission serum cTnI had
a greater prevalence of prior coronary artery disease,
hypertension and chronic renal insufficiency when com-
pared to their counterparts with normal levels. Blood
glucose and serum admission pH were inversely propor-
tional as seen in Figure 2.
Subjects with elevated serum cTnI had a significantly
higher incidence of post discharge MACE when compared
to normal subjects (Table 3). The increase resulted from a
high incidence of myocardial infarction post discharge.







Chronic Renal Insufficiency 0.680
Elevated Serum CK-MB <0.0001
Abbreviations: CAD = Coronary Artery Disease; CK-MB = Creatine Kinase – MB.in the subjects with elevated admission serum cTnI when
compared to their normal counterparts.Factors that predict elevated cTnI
Table 4 shows the factors that made significant con-
tributions to cTnI elevation. A history of coronary
disease, low pH (less than 7.1), and elevated CK-MB
levels were independent predictors for an elevated
cTnI level.Factors that predict MACE
Table 5 shows the contribution of clinical factors to risk
for MACE following hospital discharge. Using multivari-
ate logistic regression, a statistically significant relation
was only found for an elevated admission serum cTnI,
however pH also shows a strong trend toward influen-
cing MACE. The other clinical factors listed in Table 5
do not show significant relationships with MACE. The
odds ratio (OR) for pH demonstrates an increased risk
of MACE for decreased levels of pH. Independent ana-
lysis of pH influence on MACE using univariate logistic
regression identified a serum admission pH of less than
7.1 as statistically significant independent predictor for
MACE.
Figure 3 shows a significant difference in event-free
survival from MACE when comparing patients with and
without elevated admission serum cTnI. The freedom
from MACE is significantly lower in subjects who
demonstrated elevated cTnI during hospitalization in the
absence of evidence for an acute coronary syndrome.tions in cTnI








Table 5 Multi-variable logistic regression for predicting MACE
Variable P value OR 95% C.I. low 95% C.I. high
Prior History of CAD 0.127 3.659 −0.369 2.963
Elevated cTnI 0.044 1.068 0.002 0.129
Hypertension 0.085 5.312 −0.228 3.567
Chronic Renal Insufficiency 0.122 3.510 −0.335 2.846
pH 0.055 0.21 −6.907 0.083
Age 0.630 1.013 −0.039 0.065
Gender 0.395 0.543 −2.017 0.796
Race 0.329 0.422 −2.590 0.567
Elevated CK-MB 0.638 1.004 −0.011 0.018
Abbreviations: CAD = Coronary Artery Disease; CK-MB = Creatine Kinase – MB; Cardiac Troponin-I – cTnI.
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Patients with an elevated serum cTnI at admission had
longer lengths of stay. Between the two biomarkers, only
CK-MB was a statistically significant independent pre-
dictor for length of stay (Table 6).Discussion
This study identified independent prognostic factors that
predict elevations in serum admission cTnI, and demon-
strated elevated admission serum CK-MB and cTnI as
prognostic for short and long term outcomes respectively.
As a result, we gained insight into the clinical significance
of elevated admission serum cardiac biomarkers in acute
decompensated diabetes in the absence of clinically evi-
dent ACS. In the future, these data can be used to guide
management.
An admission serum pH of less than 7.1 was demon-
strated to be an independent prognostic factor for eleva-
tions in serum admission cTnI. To our knowledge, this
is the first study to demonstrate a relationship between
serum pH and elevated serum troponin. Our study sup-
ports the concept put forth by Moller et al., who noted
that patients with elevated cTnI did not have angio-
graphic evidence of coronary artery disease but had
serum admission pH values of less than 6.9 [4].Table 6 Multi-variable linear regression for predicting length
Variables Considered B Coefficient
Age 0.071
Gender −0.443






Abbreviations: CK-MB = Creatine Kinase – MB; Cardiac Troponin-I – cTnI.What accounts for the correlation between cTnI and
serum pH in the context of this study is unclear, and
remains to be elucidated. A potential explanation high-
lights a complex dynamic between pH and intracellular
calcium. As a result of severe acidemia, there is an increase
in intracellular calcium which activates multiple biochem-
ical pathways including proteolysis and myocardial stun-
ning culminating in increased serum cTnI [23-28].
Approximately 40% of the patients with an elevated
serum admission cTnI had a documented prior history of
CAD. Regression analysis demonstrated a prior history of
CAD as a prognostic factor for elevated cTnI. Acute de-
compensated diabetes is characterized by increased levels
of counter-regulatory hormones which increase myocar-
dial oxygen demand [14-16]. In such a population, the
added effect of CAD likely impairs blood flow, exacerbat-
ing a supply–demand mismatch, resulting in myonecrosis
and elevations in cTnI.
Logistic regression models identified an elevated ad-
mission serum cTnI as the only statistically significant
variable for the long term composite outcome, MACE.
Of interest is the finding that CK-MB was not correlated
with the long term MACE outcome. Furthermore, an ele-
vated admission serum cTnI proved to be a better pre-
dictor for MACE than a prior history of CAD (p = 0.127).
MACE was primarily driven by myocardial infarction, thusof hospital stay









Figure 3 Graphical Representation of Serum Glucose versus
Serum pH At Time of Admission.
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statistically significant independent predictor. More likely,
MACE incidence represents multiple pathophysiologic
mechanisms, independent of a prior history of CAD alone.
One factor, likely playing a major role in this cohort is
insulin resistance. Recent literature has recognized more
aggressive forms of type 2 diabetes marked by greater insu-
lin resistance [16,20,29-34]. When these patients decom-
pensate, they have increased production of ketoacids and
more severe acidemia. Over time, insulin resistance leads to
increased levels of pro-inflammatory cytokines like CRP
and homocysteine that accelerate atherogenesis, plaque
rupture, and MACE. This study noted an admission serum
pH of less than 7.1 to trend toward statistical significance
in an unadjusted logistic regression, and after adjusting for
other variables, demonstrated a statistical significance for
MACE. Demographically, patients with such aggressive
forms of diabetes mellitus tend to be African American, in
major urban cities. In comparison, 70% of the patients in
our study were African Americans in a major urban city.
The data suggest that patients in our study have a more ag-
gressive form of diabetes mellitus that predisposes them to
MACE independent of a prior history of CAD, and thus are
at increased risk.
Concomitantly, in the context of non-diabetic patients
status-post myocardial infarction, Knudsen et al. advance
our premise. In an article published in 2010, they present
a preponderance of evidence which highlights the connec-
tion between pro-inflammatory cytokines and deranged
blood glucose control [35].
Studies by Hernandez et al. noted that 21% of diabetics
have silent ischemia, and Zheng et al., suggest patients
with diabetes have a chronic level of myocardial injury,
and identified a correlation with blood glucose and ele-
vated levels of serum hs-cTnT [36,37]. Populations suchas this cohort, which stand at increased risk for adverse
cardiac events underscore the need for future studies
that further characterize a complex pathway.
Our findings corroborate those of Al-Mallah et al. who
identified cTnI as prognostic for long term cardiovascu-
lar events in the context of DKA [38]. This study dif-
fered in that we demonstrated a different relationship of
MACE to Troponin and to CK-MB. Further, our study
identified independent prognostic variables that predict
elevations in serum cTnI, lending an objective basis to
explain their clinical significance. Further, we assessed
short term outcomes, and identified CK-MB as an inde-
pendent predictor for length of hospital stay. Thus, we
define a novel role for CK-MB in the context of acute
decompensated diabetes. Regarding patient characteristics,
while both studies were relatively small, our study had nearly
twice as many participants enrolled (n = 264 v n = 96) and
our average length of follow up was nearly twice that of the
prior study (40 months v 24 months).
Study limitations
This study was retrospective with a small sample size. In
the future there is a need for larger multicenter pro-
spective studies. Additionally, we lacked angiographic
evidence at time of admission required to characterize
coronary anatomy and thus patients were excluded
based upon clinical information alone.
Conclusions and clinical implications
As a result of this study, we have identified independent
prognostic factors which can help guide clinical manage-
ment and predict elevations in cTnI, as well as short
term and long term outcomes. While a prior history of
CAD. Disease plays a key pathophysiologic role, the se-
verity of acidemia appears to be equally important. cTnI
and CK-MB should be measured in all patients with
acute decompensated diabetes, if elevated, in the absence
of clinically evident ACS, findings in this study identify a
patient population that is at increased risk for a longer
hospital stay in the short term, and increased risk for
MACE post-discharge.
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